Skip to main content
. 2013 Aug 27;170(2):403–414. doi: 10.1111/bph.12284

Figure 6.

Figure 6

Effect of 3-hydroxyflavone and its structural analogues on transactivation of the LBD of hCAR-SV23, hCAR-SV24, and hCAR-WT. Cultured HepG2 cells were co-transfected with a receptor expression plasmid or the pM empty vector, pCMV6-XL4-hRXRα (except for the hCAR-WT assay), pGL4.74[hRluc/TK] internal control plasmid, and pFR-luc reporter plasmid, as described under Methods. The receptor expression plasmids were (A) pM-hCAR-SV23-LBD, (B) pM-hCAR-SV24-LBD, and (C) pM-hCAR-WT-LBD. Transfected cells were treated with DMSO (0.1% v/v; vehicle), a flavonol (3-hydroxyflavone, galangin, datiscetin, kaempferol, quercetin, isorhamnetin, or tamarixetin; each at 30 μM), TCPOBOP (0.25 μM), DEHP (10 μM), or CITCO (10 μM). In the hCAR-WT assay, androstanol (10 μM; inverse agonist of hCAR-WT) was added to each treatment group. Firefly luciferase and R. reniformis luciferase activities were quantified and normalized as described under Methods. Data are expressed as mean ± S.E.M. for three independent experiments performed in triplicate. *, significantly different from the same treatment group transfected with the empty vector and the vehicle-treated control group transfected with the same receptor expression plasmid (P < 0.05).